142 related articles for article (PubMed ID: 24684741)
1. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies.
Croze LE; Tetaz R; Roustit M; Malvezzi P; Janbon B; Jouve T; Pinel N; Masson D; Quesada JL; Bayle F; Zaoui P
Transpl Int; 2014 Aug; 27(8):775-83. PubMed ID: 24684741
[TBL] [Abstract][Full Text] [Related]
2. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
3. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors.
Ruiz San Millán JC; López-Hoyos M; Segundo DS; Quintela E; Rodrigo E; Gómez-Alamillo C; Romón I; Arias M
Transpl Int; 2014 Aug; 27(8):847-56. PubMed ID: 24707885
[TBL] [Abstract][Full Text] [Related]
5. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.
Tagliamacco A; Cioni M; Comoli P; Ramondetta M; Brambilla C; Trivelli A; Magnasco A; Biticchi R; Fontana I; Dulbecco P; Palombo D; Klersy C; Ghiggeri GM; Ginevri F; Cardillo M; Nocera A
Transpl Int; 2014 Jul; 27(7):667-73. PubMed ID: 24629017
[TBL] [Abstract][Full Text] [Related]
6. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?
Grimbert P; Thaunat O
Transpl Int; 2017 Jul; 30(7):647-657. PubMed ID: 28445619
[TBL] [Abstract][Full Text] [Related]
8. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T
Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
[TBL] [Abstract][Full Text] [Related]
11. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations.
Dieplinger G; Ditt V; Arns W; Huppertz A; Kisner T; Hellmich M; Bauerfeind U; Stippel DL
Transpl Int; 2014 Jan; 27(1):60-8. PubMed ID: 24131087
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Mediated Rejection Due to Donor-Specific HLA-DQB1 and DQA1 Antibodies After Kidney Transplantation: A Case Report.
Thammanichanond D; Tammakorn C; Worawichawong S; Kantachuvesiri S
Transplant Proc; 2020; 52(6):1931-1936. PubMed ID: 32444122
[TBL] [Abstract][Full Text] [Related]
14. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
15. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
16. Donor-specific antibody to trans-encoded donor HLA-DQ heterodimer.
Habig DF; Gaspari JL; Lokhandwala PM; Domen RE; Abendroth CS; Kadry Z; Ghahramani N; Shah RA; Jain A; Shike H
Hum Immunol; 2015 Aug; 76(8):587-90. PubMed ID: 26382246
[TBL] [Abstract][Full Text] [Related]
17. Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014.
Girerd S; Schikowski J; Girerd N; Duarte K; Busby H; Gambier N; Ladrière M; Kessler M; Frimat L; Aarnink A
BMC Nephrol; 2018 Sep; 19(1):232. PubMed ID: 30219043
[TBL] [Abstract][Full Text] [Related]
18. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of Kidney Transplant Patients on the Allograft Function, Loss, Effects of HLA-DQB1-DSA
Cunha APL; Fabreti-Oliveira RA; Lasmar MF; Garcia JC; Vilela TP; Nascimento E
Transplant Proc; 2021 Sep; 53(7):2188-2196. PubMed ID: 34420780
[TBL] [Abstract][Full Text] [Related]
20. Terasaki Epitope Mismatch Burden Predicts the Development of De Novo DQ Donor-Specific Antibodies and are Associated With Adverse Allograft Outcomes.
Willicombe M; Blow M; Santos-Nunez E; Freeman C; Brookes P; Taube D
Transplantation; 2018 Jan; 102(1):127-134. PubMed ID: 28731902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
